Skip to Content

Tafenoquine Dosage

Medically reviewed by Drugs.com. Last updated on Nov 25, 2020.

Applies to the following strengths: 150 mg; 100 mg

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Malaria

300 mg orally once as a single dose

Comments:
-Limitations of Use:
---This drug is not indicated for the treatment of acute Plasmodium vivax malaria.
---Concomitant use of this drug with antimalarials other than chloroquine is not recommended due to the risk of recurrence of P vivax malaria.
-This drug should be coadministered on the first or second day of chloroquine therapy for acute P vivax malaria.
-A repeat dose is recommended if vomiting occurs within 1 hour after dosing; re-dosing should not be attempted more than once.

Use: For the radical cure (prevention of relapse) of P vivax malaria in patients receiving chloroquine therapy for acute P vivax infection

Usual Adult Dose for Malaria Prophylaxis

Loading dose: 200 mg orally once a day for 3 days
Maintenance dose: 200 mg orally once a week
Terminal prophylaxis dose: 200 mg orally once as a single dose

Duration of therapy: Up to 6 months of continuous dosing

Comments:
-The loading dose should be administered for each of the 3 days prior to travel to malarious area.
-The maintenance dose should be started 7 days after the last loading dose and should be continued while in the malarious area.
-The terminal prophylaxis regimen should be administered 7 days after the last maintenance dose in the week after exit from malarious area.
-The full course of therapy should be completed (including the loading dose, maintenance dose, and terminal dose).
-To replace missed dose(s):
---If 1 loading dose is missed: 1 dose of 200 mg so that a total of 3 daily loading doses have been administered; the maintenance dose should be started 1 week after the last loading dose
---If 2 loading doses are missed: 2 doses of 200 mg on 2 consecutive days so that a total of 3 daily loading doses have been administered; the maintenance dose should be started 1 week after the last loading dose
---If 1 maintenance (weekly) dose is missed: 1 dose of 200 mg on any day up to the time of the next scheduled weekly dose
---If 2 maintenance (weekly) doses are missed: 1 dose of 200 mg on any day up to the time of the next scheduled weekly dose
---If at least 3 maintenance (weekly) doses are missed: 2 doses of 200 mg, administered as 200 mg once a day for 2 days up to the time of the next scheduled weekly dose
---If the terminal prophylaxis dose is missed: 1 dose of 200 mg as soon as remembered

Use: For the prophylaxis of malaria

Usual Pediatric Dose for Malaria

16 years or older: 300 mg orally once as a single dose

Comments:
-Limitations of Use:
---This drug is not indicated for the treatment of acute P vivax malaria.
---Concomitant use of this drug with antimalarials other than chloroquine is not recommended due to the risk of recurrence of P vivax malaria.
-This drug should be coadministered on the first or second day of chloroquine therapy for acute P vivax malaria.
-A repeat dose is recommended if vomiting occurs within 1 hour after dosing; re-dosing should not be attempted more than once.

Use: For the radical cure (prevention of relapse) of P vivax malaria in patients receiving chloroquine therapy for acute P vivax infection

Renal Dose Adjustments

Renal dysfunction: Monitoring for drug-related side effects recommended.

Liver Dose Adjustments

Liver dysfunction: Monitoring for drug-related side effects recommended.

Precautions

CONTRAINDICATIONS:
-Glucose-6-phosphate dehydrogenase (G6PD) deficiency or unknown G6PD status (due to risk of hemolytic anemia)
-Breastfeeding when infant is G6PD deficient or if G6PD status of infant is unknown
-Known hypersensitivity to the active component, any of the ingredients, or other 8-aminoquinolines
-For the prophylaxis of malaria: History of psychotic disorders or current psychotic symptoms (i.e., hallucinations, delusions, and/or grossly disorganized behavior)

For the prophylaxis of malaria: Safety and efficacy have not been established in patients younger than 18 years.
For the radical cure of P vivax malaria: Safety and efficacy have not been established in patients younger than 16 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Test all patients for G6PD deficiency before prescribing this drug.
-Test females of reproductive potential for pregnancy before starting this drug.
-Administer with food (to increase systemic absorption).
-Swallow tablets whole; do not break, crush, or chew.
-For the prophylaxis of malaria: Complete the full course of therapy (including the loading dose, maintenance dose, and terminal dose).
-For the radical cure of P vivax malaria: Do not use to treat acute P vivax malaria; coadminister this drug on the 1st or 2nd day of chloroquine therapy for acute P vivax malaria.
-For the radical cure of P vivax malaria: Administer an additional dose if vomiting occurs within 1 hour after dosing; do not attempt to re-dose more than once.

Storage requirements:
-Store at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F).
-Protect from moisture.
-Blister card (100 mg tablets): Dispense only in original carton.
-Bottle (150 mg tablets): Store in original container with desiccant inside; keep bottle tightly closed.

Monitoring:
-General: Pregnancy testing in females of reproductive potential (before therapy); for drug-related side effects in patients with renal and/or liver dysfunction
-Hematologic: For clinical signs/symptoms of hemolysis
-Metabolic: For G6PD deficiency (before prescribing)

Patient advice:
-Read the US FDA-approved patient labeling (Medication Guide [for the prophylaxis of malaria]; Patient Information [for the radical cure of P vivax malaria]).
-Promptly seek medical advice if symptoms of hemolytic anemia or methemoglobinemia occur; contact healthcare provider if dark/darker lips or urine develop.
-Females of reproductive potential: Avoid pregnancy or use effective contraception during therapy and for 3 months after the last dose of this drug.
-For the prophylaxis of malaria: Seek medical attention as soon as possible if hallucinations, delusions, or confused thinking occur during therapy; seek prompt evaluation by medical professional if other psychiatric symptoms (e.g., changes in mood, anxiety, insomnia, nightmares) last more than 3 days or are severe.
-For the radical cure of P vivax malaria: Promptly seek medical advice if new or worsening psychiatric symptoms develop.
-Promptly seek medical advice if symptoms of hypersensitivity reactions develop.
-For the prophylaxis of malaria: Avoid missing doses and complete the entire course of therapy.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.